# CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA

> **NCT07451236** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chang Yingjun** · enrollment: 18 (estimated)

## Conditions studied

- Transplantation Candidates With Hematological Diseases

## Interventions

- **BIOLOGICAL:** CD19-BCMA dual nanobody based CAR-T Cells

## Key facts

- **NCT ID:** NCT07451236
- **Lead sponsor:** Chang Yingjun
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07451236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07451236, "CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07451236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*